Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.51 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20133503 | 0.92 | MMP3 (0.47) | SSTR3CALCRLLTA4HMMP3SIRT2 | |
| SCHEMBL22010347 | 0.92 | SSTR3 (0.51) | SSTR3CALCRLLTA4HMMP3ECE1 | |
| SCHEMBL12245289 | 0.89 | SSTR3 (0.53) | SSTR3CALCRLLTA4HMMP3ECE1 | |
| SCHEMBL26439273 | 0.87 | SSTR3 (0.53) | SSTR3CALCRLLTA4HMMP3ECE1 | |
| SCHEMBL21474554 | 0.81 | SSTR3 (0.55) | SSTR3CALCRLLTA4HMMP3ECE1 | |
| SCHEMBL25475432 | 0.81 | SSTR3 (0.54) | SSTR3CALCRLLTA4HMMP3ECE1 | |
| SCHEMBL19231508 | 0.81 | SSTR3 (0.54) | SSTR3CALCRLLTA4HMMP3F2 | |
| SCHEMBL19403504 | 0.81 | SSTR3 (0.54) | SSTR3CALCRLLTA4HMMP3ECE1 | |
| SCHEMBL25062089 | 0.79 | MMP2 (0.53) | MMP3 | |
| SCHEMBL23106089 | 0.79 | F2 (0.47) | SSTR3F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10799596-B2 | Pyrrolobenzodiazepine-antibody conjugates | ADC THERAPEUTICS S.A. (CH) | 2020-10-13 | — | — | US | disclosed |
| US-10780096-B2 | Pyrrolobenzodiazepine-antibody conjugates | ADC THERAPEUTICS SA (CH) | 2020-09-22 | — | — | US | disclosed |
| US-20180193480-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | MEDIMMUNE LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20170258934-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258934-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | IL2RA, CD2, CD4 | SSTR3 1560/4885CALCRL 4116/4885LTA4H 2083/4885 |
| US-10780096-B2 | Pyrrolobenzodiazepine-antibody conjugates | IL2RA, CD2, CD4 | SSTR3 1560/4885CALCRL 4116/4885LTA4H 2083/4885 |
| US-10799596-B2 | Pyrrolobenzodiazepine-antibody conjugates | IL2RA, CD4, IL2 | SSTR3 2193/4885CALCRL 3939/4885LTA4H 2766/4885 |
| US-20180193480-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | IL2RA, CD4, IL2 | SSTR3 2193/4885CALCRL 3939/4885LTA4H 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.